MedTrace Logo

Low Dose Aspirin for the Prevention of Preeclampsia

NCT01890005 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 476

Last updated 2013-07-01

No results posted yet for this study

Summary

Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over the world. The use of low dose aspirin has been mentioned in several studies with promising results. The investigators decided to evaluate the use of low dose aspirin, starting between 13 and 16 weeks of pregnancy, based on clinical characteristics only to reduce the incidence of preeclampsia.

Conditions

Interventions

DRUG

Aspirin

Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.

DRUG

Placebo

Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.

Sponsors & Collaborators

  • Saint Thomas Hospital, Panama

    lead OTHER

Principal Investigators

  • Osvaldo Reyes, MD · Saint Thomas Maternity Hospital

  • Rodrigo Velardee, MD · Saint Thomas Maternity Hospital

  • Ameth Hawkins, MD · Saint Thomas Maternity Hospital

  • Ana Moreno, MD · Saint Thomas Maternity Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • Panama

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01890005 on ClinicalTrials.gov